AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints
MT Newswires Live
Yesterday
AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free survival, the company said Thursday.
Trial results, which covered 393 patients, demonstrated significantly higher objective response rate and improved progression-free survival with etentamig compared with standard available therapies, AbbVie said.
AbbVie plans to discuss the phase 3 study's results with regulatory authorities globally to determine the next development steps for etentamig, according to the statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.